BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company offers a substance use disorder recovery program, Beat Addiction Recovery, which includes cognitive behavioral therapy modules, peer support through a mobile application, and medication prescription from an independent treating physician; and the UnCraveRx weight loss management program, a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists. It also develops BICX101, an injectable and implantable naltrexone product; BICX102, a long-acting naltrexone implant that can last several months for opioid dependence and alcohol use disorders; and BICX104, a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder. The company licenses and distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. was founded in 2009 and is based in Anaheim, California.
| Business Activity | PASS |
| Debt Ratio (0.24%) | PASS |
| Cash Ratio (0.02%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2025-11-14 | -0.06 | -0.11 | -83.3% |
| 2015-11-16 | — | Pending | -- |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $214.5K | -$831.2K | -$671.7K | $189.4K | -$587.0K | -0.03 |
| 2025-12-31 | -$151.1K | $552.6K | -$398.0K | $185.9K | $466.3K | — |
| 2025-09-30 | $635.2K | -$1.9M | -$501.2K | $276.4K | -$1.1M | -0.11 |
| 2025-06-30 | $178.2K | -$1.2M | -$1.1M | $178.2K | -$1.3M | -0.07 |
| 2025-03-31 | $134.9K | -$841.4K | -$569.6K | $134.9K | -$524.0K | -0.06 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | LUCIDO LOUIS CHARLES | President | 1,428,647 | -- |
| 2024-12-31 | FELIX LOURDES | Chief Executive Officer | 752,979 | -- |
| 2024-06-28 | LUCIDO LOUIS CHARLES | President | 44,220 | -- |
| 2024-06-28 | INGARGIOLA LUISA | Director | 15,770 | -- |
| 2024-06-28 | FELIX LOURDES | Chief Executive Officer | 10,204 | -- |
| 2024-05-31 | LUCIDO LOUIS CHARLES | President | 22,831 | -- |
$13.4M
-1.01
0.173
$797.2K
$2.2M
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| KDK | 0.234 |
| IDT | 0.191 |
| IBKR | 0.181 |
| MNST | 0.177 |
| BOUBYAN.KW | 0.174 |
| Ticker | Correlation |
|---|---|
| RIBT | -0.178 |
| 4018.SR | -0.175 |
| ATC.KW | -0.142 |
| LPTVQ | -0.138 |
| DHTI | -0.134 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.